AUTL vs. BCRX, SRRK, CGEM, IMTX, PROK, RLAY, MESO, FDMT, PRME, and RGNX
Should you be buying Autolus Therapeutics stock or one of its competitors? The main competitors of Autolus Therapeutics include BioCryst Pharmaceuticals (BCRX), Scholar Rock (SRRK), Cullinan Oncology (CGEM), Immatics (IMTX), ProKidney (PROK), Relay Therapeutics (RLAY), Mesoblast (MESO), 4D Molecular Therapeutics (FDMT), Prime Medicine (PRME), and REGENXBIO (RGNX). These companies are all part of the "biological products, except diagnostic" industry.
Autolus Therapeutics (NASDAQ:AUTL) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, community ranking, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.
Autolus Therapeutics has a net margin of 0.00% compared to BioCryst Pharmaceuticals' net margin of -58.69%. BioCryst Pharmaceuticals' return on equity of 0.00% beat Autolus Therapeutics' return on equity.
BioCryst Pharmaceuticals received 258 more outperform votes than Autolus Therapeutics when rated by MarketBeat users. However, 67.18% of users gave Autolus Therapeutics an outperform vote while only 66.43% of users gave BioCryst Pharmaceuticals an outperform vote.
72.8% of Autolus Therapeutics shares are held by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. 25.7% of Autolus Therapeutics shares are held by company insiders. Comparatively, 4.4% of BioCryst Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Autolus Therapeutics has higher earnings, but lower revenue than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, BioCryst Pharmaceuticals had 3 more articles in the media than Autolus Therapeutics. MarketBeat recorded 16 mentions for BioCryst Pharmaceuticals and 13 mentions for Autolus Therapeutics. BioCryst Pharmaceuticals' average media sentiment score of 0.98 beat Autolus Therapeutics' score of 0.67 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media.
Autolus Therapeutics currently has a consensus price target of $8.70, suggesting a potential upside of 98.18%. BioCryst Pharmaceuticals has a consensus price target of $14.00, suggesting a potential upside of 122.93%. Given BioCryst Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe BioCryst Pharmaceuticals is more favorable than Autolus Therapeutics.
Autolus Therapeutics has a beta of 2.03, suggesting that its stock price is 103% more volatile than the S&P 500. Comparatively, BioCryst Pharmaceuticals has a beta of 1.96, suggesting that its stock price is 96% more volatile than the S&P 500.
Summary
BioCryst Pharmaceuticals beats Autolus Therapeutics on 11 of the 18 factors compared between the two stocks.
Get Autolus Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AUTL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AUTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Autolus Therapeutics Competitors List
Related Companies and Tools
